Market capitalization | $15.19m |
Enterprise Value | $13.25m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.75 |
P/S ratio (TTM) P/S ratio | 0.86 |
P/B ratio (TTM) P/B ratio | 1.02 |
Revenue growth (TTM) Revenue growth | 4.12% |
Revenue (TTM) Revenue | $17.68m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:
2 Analysts have issued a Ekso Bionics Holdings, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 18 18 |
4%
4%
|
|
Gross Profit | 9.17 9.17 |
9%
9%
|
|
EBITDA | -9.79 -9.79 |
34%
34%
|
EBIT (Operating Income) EBIT | -12 -12 |
27%
27%
|
Net Profit | -11 -11 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ekso Bionics Holdings, Inc. engages in the design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following business segments: EksoHealth, EksoWorks, and Other. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.
Head office | United States |
CEO | Scott Davis |
Employees | 70 |
Founded | 2012 |
Website | www.eksobionics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.